|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2006-12-12
|
|
pubmed:abstractText |
Inhibitors of the enzyme dipeptidyl peptidase IV (DPP IV) provide a strategy for the treatment of type 2 diabetes. DPP IV rapidly inactivates the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Inhibition of DPP IV prolongs and enhances the activity of endogenous GLP-1 and GIP, which serve as important prandial stimulators of insulin secretion and regulators of blood glucose control. In clinical trials DPP IV inhibitors (or 'gliptins') have shown efficacy and tolerability in the management of hyperglycaemia in type 2 diabetes, without causing weight gain or hypoglycaemia.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Adamantane,
http://linkedlifedata.com/resource/pubmed/chemical/Adenosine Deaminase,
http://linkedlifedata.com/resource/pubmed/chemical/Adenosine Deaminase Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Blood Glucose,
http://linkedlifedata.com/resource/pubmed/chemical/DPP4 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Dipeptidyl Peptidase 4,
http://linkedlifedata.com/resource/pubmed/chemical/Dipeptidyl-Peptidase IV Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Gastric Inhibitory Polypeptide,
http://linkedlifedata.com/resource/pubmed/chemical/Glucagon-Like Peptide 1,
http://linkedlifedata.com/resource/pubmed/chemical/Glycoproteins,
http://linkedlifedata.com/resource/pubmed/chemical/Hypoglycemic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Isoenzymes,
http://linkedlifedata.com/resource/pubmed/chemical/Nitriles,
http://linkedlifedata.com/resource/pubmed/chemical/Protease Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Pyrazines,
http://linkedlifedata.com/resource/pubmed/chemical/Pyrrolidines,
http://linkedlifedata.com/resource/pubmed/chemical/Triazoles,
http://linkedlifedata.com/resource/pubmed/chemical/sitagliptin,
http://linkedlifedata.com/resource/pubmed/chemical/vildagliptin
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
1479-1641
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
3
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
159-65
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:17160910-Adamantane,
pubmed-meshheading:17160910-Adenosine Deaminase,
pubmed-meshheading:17160910-Adenosine Deaminase Inhibitors,
pubmed-meshheading:17160910-Animals,
pubmed-meshheading:17160910-Blood Glucose,
pubmed-meshheading:17160910-Clinical Trials as Topic,
pubmed-meshheading:17160910-Diabetes Mellitus, Type 2,
pubmed-meshheading:17160910-Dipeptidyl Peptidase 4,
pubmed-meshheading:17160910-Dipeptidyl-Peptidase IV Inhibitors,
pubmed-meshheading:17160910-Drug Evaluation, Preclinical,
pubmed-meshheading:17160910-Gastric Inhibitory Polypeptide,
pubmed-meshheading:17160910-Glucagon-Like Peptide 1,
pubmed-meshheading:17160910-Glycoproteins,
pubmed-meshheading:17160910-Humans,
pubmed-meshheading:17160910-Hypoglycemic Agents,
pubmed-meshheading:17160910-Isoenzymes,
pubmed-meshheading:17160910-Nitriles,
pubmed-meshheading:17160910-Protease Inhibitors,
pubmed-meshheading:17160910-Pyrazines,
pubmed-meshheading:17160910-Pyrrolidines,
pubmed-meshheading:17160910-Triazoles
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Dipeptidyl peptidase IV (DPP IV) inhibitors: A newly emerging drug class for the treatment of type 2 diabetes.
|
|
pubmed:affiliation |
School of Biological Sciences, Queens University Belfast, Belfast, BT9 5AG, UK. b.green@qub.ac.uk
|
|
pubmed:publicationType |
Journal Article,
Review
|
